Webinars

View On-Demand Webinars That Demonstrate the Clinical Benefit and Patient Impact of DEFINITY®

A Clearer Echo: Improve Your Lab Efficiency and Patient Outcomes

Martin E. Goldman, MD, discusses the impact of DEFINITY® in COVID-19 patients, and Paul Bhella, MD, FASE, FAHA, FACC, explores clinical case studies and data illustrating the benefits of DEFINITY® while reviewing ASE guidelines.

Enhanced Optimization Techniques for Contrast Echo

Steven Walling, BS, RCS, RDCS, FASE, presents “Enhanced Optimization Techniques for Contrast Echo.”

Contrast Echo: See in High DEF(INITY)™, Experience the Impact

Jonathan R. Lindner, MD, Lissa Sugeng, MD, MPH, and Rajesh Janardhanan, MD, present the Lantheus 2015 ASE Science & Technology Theater Program.

Are You Optimizing the Use of Contrast Echocardiography? A Case-Based Discussion

Anita M. Kelsey, MD, and Steven Walling, RDCS, explore 2 cases to illustrate the importance of teamwork, operational efficiency, and the appropriate use of DEFINITY® in achieving quality echocardiographic imaging.

Case-Based Review of Clinical Safety: Contrast Echocardiography in the Acute Critical Care Setting

Eyal Herzog, MD, shows how the appropriate use of DEFINITY® assisted in achieving quality diagnostic imaging in critically ill patients with suboptimal echocardiograms.

Enhanced Echocardiography: It's What You Don't See That Matters

Ben Lin, MD, Theresa Green, RDCS, and Sean McMahon, MD, present the Lantheus 2019 ASE Science & Technology Theater Program.

COVID-19: Realizing the Value of Enhanced Echo

Smadar Kort, MD, FACC, FASE, FAHA, presents “Cardiovascular Complications of COVID-19” and Susan Dillon, RDCS, FASE, presents “Echo Lab Efficiencies Expedite Patient Management Decisions.”

Contrast Echo Guidelines: See the Impact

Paul Braum, BS, RVT, RDCS, RVS, FASE, presents “Contrast Echo Guidelines: See the Impact.”

Clinical Case Reviews: The Impact of Contrast Echocardiography

Amr E. Abbas, MD, and Judy Malone, BS, RDCS, explore clinical case studies illustrating how an efficient implementation of DEFINITY® across clinical settings may impact diagnostic outcomes and patient management decisions.

Who Benefits From the Use of Contrast Echocardiography?

Vincent Sorrell, MD, Michael Rampoldi, ACS, and Kirsten Tolstrup, MD, highlight the advantages contrast echocardiography has over unenhanced echo in diagnostic outcomes, patient management, and cost effectiveness.

Enhanced Echo at the Point of Care: Impact on Quality and Outcomes

Jayanta T. Mukherjee, MD, and Daniel F. Skully, MD, share their experiences and insights on the diagnostic impact and clinical value of DEFINITY® at the point of care, highlighting the impact DEFINITY® has on the critically ill.

Are You Really Improving Quality With Contrast Echocardiography?

Paul S. Bhella, MD, Paul Braum, BS, RDCS, and Joan S. Crawford, DO, present the Lantheus 2016 ASE Science & Technology Theater Program.

Achieving Workflow Efficiency With Contrast Echocardiography: Best Practices and Case-Based Discussion

Bret Rogers, MD, and Chad Bousanti, RCS, share institutional experiences establishing efficient processes and logistics for effective use of DEFINITY®.

The Diagnostic Advantage of Contrast Echocardiography

Anita M. Kelsey, MD, Margaret M. Park, BS, ACS, and Kevin Wei, MD, present the Lantheus 2017 ASE Science & Technology Theater Program.

The Value of Contrast Echocardiography Across Multiple Care Settings

Dennis Mihalatos, MD, and Robert W. Biederman, MD, lead a case-based discussion highlighting how DEFINITY® impacts diagnostic outcomes and patient management across multiple patient care settings.

Improving Quality and Efficiency in Echocardiography

Omar Husseini, MD, presents “Efficiently implement the appropriate use of DEFINITY® within your institution” and Gina Conigliaro-Brito, MHA, RDCS, RCS, RVS, presents “Establishing a Sonographer Contrast Administration Protocol.”

The Impact of Ultrasound Contrast on Patient Care

Kevin Wei, MD, FACC, FASE, Professor of Medicine Cardiovascular Institute Oregon Health & Sciences University, presents “The Impact of Ultrasound Contrast on Patient Care.”

Improve Patient Management by Selecting the Appropriate Echo Contrast Agent: A Case-Based Discussion

Kamran Shaikh, MD, and Andy Isaacks, RDCS, use actual cases to highlight the important role DEFINITY® has in establishing quality-driven echocardiography and improving patient outcomes.

Quality Performance of Using DEFINITY® in the Echocardiography Lab

Michael Rampoldi, ACS, RDCS, RVT, FASE, presents “Quality Performance of Using DEFINITY® in the Echocardiography Lab.”

COVID-19: Clinical Experience With DEFINITY® From the Front Line in NYC

Martin Goldman, MD, Lori Croft, MD, and Samantha Buckley, RDCS, share their experience treating patients and provide insight into the use of DEFINITY® during the COVID-19 pandemic.

The Benefits of Contrast on Patient Management

Vincent L. Sorrell, MD, FACC, FASE, presents “The Benefits of Contrast on Patient Management.”

The Significance of Accurate Endocardial Border Delineation

Theresa Green, RDCS, Echocardiography Advanced Coordinator Piedmont Hospital, presents “The Significance of Accurate Endocardial Border Delineation.”

Modern-Day Contrast Themes

William A. Zoghbi, MD, Michael L. Main, MD, and Lissa Sugeng, MD, MPH, present the Lantheus 2014 ASE Science & Technology Theater Program.

INDICATION

DEFINITY® is indicated, after activation, for use in adult and pediatric patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.

IMPORTANT SAFETY INFORMATION

BOXED WARNING: SERIOUS CARDIOPULMONARY REACTIONS

Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren-containing microsphere administration. Most serious reactions occur within 30 minutes of administration.

Assess all patients for the presence of any condition that precludes DEFINITY^® administration.
Always have resuscitation equipment and trained personnel readily available.

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION

IMPORTANT SAFETY INFORMATION

BOXED WARNING: SERIOUS CARDIOPULMONARY REACTIONS

Assess all patients for the presence of any condition that precludes DEFINITY® administration.
Always have resuscitation equipment and trained personnel readily available.

CONTRAINDICATIONS:

Contraindicated in patients with known or suspected hypersensitivity to perflutren lipid microsphere or its components, such as polyethylene glycol (PEG).

WARNINGS AND PRECAUTIONS:

Serious Cardiopulmonary Reactions have occurred during or following administration. The risk for these reactions may be increased among patients with unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias).

Serious Hypersensitivity Reactions have been observed during or shortly following administration including anaphylaxis, with manifestations that may include death. DEFINITY® contains PEG and may increase risk of serious reactions including death in patients with prior hypersensitivity reaction(s) to PEG. Clinically assess patients for prior hypersensitivity reactions to products containing PEG. Monitor all patients for hypersensitivity reactions.

Systemic Embolization may occur in patients with a cardiac shunt. Assess patients with shunts for embolic phenomena following administration. DEFINITY® is only for intravenous administration and must not be administered by intra-arterial injection.

There is a risk of Ventricular Arrhythmia Related to High Mechanical Index. Additionally, end-systolic triggering with high mechanical indices has been reported to cause ventricular arrhythmias. The maximum recommended mechanical index for use with DEFINITY® is 0.8 in adult patients and 0.3 in pediatric patients.

Acute Pain Episodes in Patients with Sickle Cell Disease (SCD) shortly following administration have been reported. Discontinue DEFINITY® in SCD patients experiencing new or worsening pain.

ADVERSE REACTIONS:

The most common adverse reactions (≥0.5%) are headache, back/renal pain, flushing, nausea, chest pain, injection site reactions, and dizziness.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch or call 1-800-FDA-1088.

Please see accompanying full Prescribing Information and Important Safety Information, including boxed WARNING regarding serious cardiopulmonary reactions.

DEFINITY® Customer Service 1.800.299.3431

BACK TO
TOP